



GP 1643

PATENT

Attorney Docket No.: 28967/35255A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AT
P#7
1-27-00

Applicant: Ferrell, R.E. *et al.*
Serial No.: 09/375,248
Filed: August 16, 1999
For: "Screening and Therapy For
Lymphatic Disorders
Involving the Flt4 Receptor
Tyrosine Kinase (VEGFR-3)"
Group Art Unit: 1643
Examiner: Not yet assigned

I hereby certify that this paper is being
deposited with the United States Postal
Service as first class mail, postage prepaid,
in an envelope addressed to: Assistant
Commissioner for Patents, Washington,
DC 20231 on this date:

January 11, 2000

RECEIVED

JAN 18 2000

Jill E. Uhl
Jill E. Uhl
Registration No. 43,213
Attorney for Applicants

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The applicants request that the documents listed on the attached Form PTO-1449 be
made of official record in the above-identified application and considered by the Examiner.

This Information Disclosure Statement is not intended to be an admission that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.


This Information Disclosure Statement is submitted before receipt of a first Office action. Accordingly, it is submitted that no fee is due in this matter under 37 C.F.R. §1.97(b). However, the Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855. A copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

January 11, 2000

By:


Jill E. Uhl
Reg/No: 43,213